期刊文献+

PEP-T节拍化疗方案治疗复发难治性淋巴瘤62例 被引量:1

原文传递
导出
摘要 目的 评价PEP-T节拍化疗治疗复发难治性淋巴瘤的临床疗效和患者不良反应.方法 62例复发难治性淋巴瘤患者给予PEP-T节拍化疗方案,具体为:泼尼松20 mg/d,早餐后口服;环磷酰胺50 mg/d,午餐后口服;依托泊苷50 mg/d,晚餐后口服;沙利度胺100 mg/d,睡前口服.酌情配合使用口服止吐药物.持续服用直至白细胞低于3.0×109/L时停药,待白细胞恢复至高于3.0×109/L时,再根据患者的耐受程度调整用法为每天1次或隔天1次给药或每周5d休息2d的给药方法,每日药量不变.结果 62例患者均可评价疗效和不良反应,总有效率(RR) 62.9%(39/62),其中完全缓解(CR)率32.3%(20/62),部分缓解(PR)率30.6%(19/62).惰性淋巴瘤与侵袭性淋巴瘤RR分别为83.3%(25/30)、43.8%(14/32),差异有统计学意义(x2=10.397,P=0.002);CR率分别为46.7%(14/30)、18.8%(6/32),差异有统计学意义(x 2=5.522,P=0.029).国际预后指数(1PI)低危组(IPI评分0~2分)与高危组(IPI评分3~5分)RR分别为64.3%(27/42)、60.0%(12/20),差异无统计学意义(x2=0.107,P=0.784);CR率分别为33.3%(14/42)、30.O%(6/20),差异无统计学意义(x2=0.069,P=1.000).患者主要不良反应为骨髓抑制、恶心、呕吐及腹泻,经治疗均可恢复,无治疗相关死亡.结论 PEP-T节拍化疗采用低剂量、持续口服给药方式,对于复发难治性淋巴瘤疗效肯定,尤其对于惰性淋巴瘤效果好,不良反应较轻,特别适合不能耐受强烈化疗的患者.
出处 《白血病.淋巴瘤》 CAS 2013年第11期682-684,共3页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献12

  • 1Sehn LH, Donaldson J, Chanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia. J Clin Oncol, 2005, 23: 5027-5033.
  • 2邹志建,徐卫,李建勇.霍奇金淋巴瘤治疗进展:第54届美国血液学会年会深度报道[J].白血病.淋巴瘤,2013,22(1):21-24. 被引量:2
  • 3O'Connor OA, Hamlin P. New drugs for the treatment of advanced- stage diffuse large cell lymphoma. Semin Hematol, 2006, 43:251-256.
  • 4Coleman M, Leonard JP, Furman RR, et al. Combination chemotherapy for refractory/relapsed lymphoma with the PEP-C (C3) regimen (daily prednisone, etoposide,procar-bazine,cyclophosphamide: low dose continuous metro-nomic multidrug. Proc Am Soc Clin Oncol, 2006, 25: Abstract 8064.
  • 5潘战和,苏安,王馨,黄慧强,张靖,吕霞.PEP-C节拍化疗方案治疗复发和难治性非霍奇金淋巴瘤23例探讨[J].中国肿瘤临床,2011,38(9):529-532. 被引量:1
  • 6Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to cmventional therapy. Blood, 2000, 96: 2943-2950.
  • 7张巧花.难治性非霍奇金淋巴瘤的诊疗策略[J].中国实用内科杂志,2005,25(6):487-489. 被引量:20
  • 8Piccart-Gebhart MJ. Mathematics and oncology:a match for life? J ClinOneol, 2003, 21: 1425-1428.
  • 9Tuma llS. Dosing study seen as victory t'w elinieal trials,umthematieal models. J Natl Cancer Inst, 2003, 95: 254-255.
  • 10Kerbel RS, Klement G, Pritehard KI, et al. Continuous low-dose anti- angiogenie/metronomie chemotherapy:from the research laloratory into the oneology clinic. Ann Oneol, 2002, 13:12-15.

二级参考文献12

  • 1陆文斌,金建华,顾小燕,王芳,李献文,张华,杨玉薇.CHOPE方案治疗侵袭性非霍奇金淋巴瘤(NHL)40例[J].中国肿瘤临床,2007,34(3):151-153. 被引量:9
  • 2Sehn LH,Donaldson J,Chanabhai M,et al.Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia[J].J Clin Oncol,2005,23(22):5027-5033.
  • 3Coiffier B.Effective immunochemotherpy for aggressivenon-Hodgkin's lymphoma[J].Semina Oncol,2004,31(1 Suppl 2):7-11.
  • 4Fisher RI.Overview of non-Hodgkins lymphoma and biology,staging,treatment[J].Semin Oncol,2003,30(2 Suppl 4):3-9.
  • 5Coleman M,Martin P,Ruan J,et al.Prednisone etoposide,procarbazine,and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring /refractory lymphoma:low-dosemetronomic,multidrug therapy[J].Cancer,2008,112(10):2228-2232.
  • 6Browder T,Butterfield CE,Kraling BM,et al.Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer[J].Cancer Res,2000,60(7):1878-1886.
  • 7Kerbel RS,Klement G,Pritchard KL,et al.Continuous low-dose anti-angiogenic/ metronomic chemotherapy:from the research laboratory into the oncology clinic[J].Ann Oncol,2002,13(1):12-15.
  • 8Gasparini G,Meo S,Comella G,et al.The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second line therapy for non-small cell lung cancer:a phase II study with biological correlates[J].Cancer J,2005,11(3):209-216.
  • 9Steinbild S,Arends J,Medinqer M,et al.Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a phase II study[J].Onkologie,2007,30(12):629-635.
  • 10Kewalramani T,Zelenetz AD,Nimer SD,et al.Rituximab and ICE as second-line therapy beforea utologouss tem cell transplantion for relapsed or primary refractory diffuse large B-cell lymphoma[J].Blood,2004,103(10):3684-3688.

共引文献20

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部